SCHEMBL10100384

SCHEMBL10100384

Cn1cc(-c2cnc(N)c(-c3nnnn3-c3ccc(OCCN4CCOCC4)c(F)c3F)c2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 3/20 0.41
LRRK2 Q5S007 8/20 0.40
ALK Q9UM73 1/20 0.39
PRKAB2 O43741 3/20 0.38
PRKAG1 P54619 3/20 0.38
PRKAA2 P54646 3/20 0.38
PRKAA1 Q13131 3/20 0.38
PRKAG3 Q9UGI9 3/20 0.38
PRKAG2 Q9UGJ0 3/20 0.38
PRKAB1 Q9Y478 3/20 0.38
KIT P10721 1/20 0.38
AXL P30530 1/20 0.37
LCK P06239 1/20 0.36
SRC P12931 1/20 0.36
FLT1 P17948 1/20 0.36
EPHA2 P29317 1/20 0.36
KDR P35968 1/20 0.36
FLT3 P36888 1/20 0.36
RPS6KA1 Q15418 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10100682 0.96 LRRK2 (0.40) METLRRK2ALKAXLPDPK1
SCHEMBL10100679 0.95 LRRK2 (0.39) METLRRK2ALKAXLPDPK1
SCHEMBL10100706 0.95 MET (0.40) METLRRK2ALKPRKAB2PRKAG1
SCHEMBL10100389 0.93 LRRK2 (0.41) METLRRK2KITMAPK1
SCHEMBL10100385 0.92 LRRK2 (0.40) METLRRK2MAPK1
SCHEMBL10100570 0.92 IKBKE (0.39) METLRRK2ALKPRKAB2PRKAG1
SCHEMBL10100568 0.91 ALK (0.40) METLRRK2ALKKITAXL
SCHEMBL10100571 0.91 LRRK2 (0.40) METLRRK2ALKPRKAB2PRKAG1
SCHEMBL10100561 0.90 ABL1 (0.39) METLRRK2ALKKITAXL
SCHEMBL10100594 0.90 MET (0.42) METLRRK2ALKKITAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518938-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-27 US disclosed
US-8518938-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-27 US disclosed
US-20120165333-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-28 US disclosed
US-20120165333-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-28 US disclosed
WO-2010048131-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165333-A1 C-MET PROTEIN KINASE INHIBITORS MET, PRKCH, ABL1 MET 1/4885LRRK2 856/4885ALK 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.